Articles related to KIDNEY CANCER/RCC

Cabozantinib plus nivolumab and ipilimumab (C-N-I) is a new combination therapy for patients with advanced renal cell carcinoma (RCC). In a phase 3 clinical trial, C-N-I was shown to be superior to sunitinib in terms of progression-free survival (PFS) and overall survival (OS). The trial enrolled 823 patients with advanced RCC who had not received prior systemic therapy. Patients were randomly assigned to receive either C-N-I (n=412) or sunitinib (n=411). The primary endpoint of the trial was PFS, and the secondary endpoint was OS. At a median follow-up of 24 months, patients who received C-N-I had a significantly longer PFS than patients who received sunitinib. The median OS for patients who received C-N-I was not reached, while the median OS for patients who received sunitinib was 22.8 months.

Taking place February 3 – 5, 2023 at the JW Marriott Scottsdale Camelback Inn Resort & Spa in Paradise Valley, Arizona, live and virtual attendees will learn how to distinguish between immunotherapy combinations in metastatic RCC, identify actionable target therapy in the treatment of metastatic lung cancer, identify targeted therapies for CNS metastases, review management of resectable melanoma – neoadjuvant versus adjuvant immune checkpoint blockade, and assess the approved and developing categories of prostate cancer patients eligible for PSMA-targeted therapy.

The authors determined the prognostic significance of CTC enumeration and the evolution of both CTC enumeration and the HP ratio over time in the largest longitudinal CTC study in mRCC to date. Potential biomarkers to predict and track response to immunotherapy in mRCC are provided by these insights into changes in both tumor burden and the molecular profile of tumor cells in response to various treatments.

With just a few exceptions (p.I157T, p.S428F, and p.T476M), CHEK2 PVs were linked to comparable cancer phenotypes regardless of the variation type. Although CHEK2 PVs were linked to breast, kidney, and thyroid malignancies, they were not linked to colorectal cancer. The prevalent p.I157T, p.S428F, and p.T476M alleles have a weaker connection with breast cancer compared to other CHEK2 PVs and were not related with non-breast malignancies. These findings might help with genetic counseling and care for those with CHEK2 PVs.

A multi-variate analysis published in Cancer Medicine, which includes a population of more than 150,000 individuals, suggests that prior cannabis use was associated with a reduced risk of renal cell carcinoma and bladder cancer in women and prostate cancer in men. A potentially conflicting finding was increased risk of some cancers in current cannabis users.

Both immune checkpoint inhibitors (ICIs) and VEGF receptor inhibitors are approved for advanced renal cell carcinoma (RCC) treatment and can cause cardiovascular events (CVs). This randomized study of avelumab plus axitinib vs. sunitinib used prospective monitoring of LVEF and serum cardiac biomarkers to assess for the development of major adverse CV events. The results indicate patients with high baseline troponin T levels and who receive combination ICI and VEGF receptor inhibitor therapy should be monitored closely for adverse cardiac events.